Gilead Sciences, Inc. (NASDAQ:GILD) has earned a consensus recommendation of “Buy” from the thirty-three analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $84.26.
A number of research firms have issued reports on GILD. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Zacks Investment Research cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Vetr cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 target price for the company. in a research note on Monday, September 4th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $83.00 target price (up from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th.
Shares of Gilead Sciences (NASDAQ:GILD) traded up $0.21 on Thursday, reaching $76.09. 9,280,267 shares of the company were exchanged, compared to its average volume of 9,197,696. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The stock has a market capitalization of $96,951.29, a P/E ratio of 7.75, a PEG ratio of -1.24 and a beta of 1.13. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company’s revenue was down 13.2% compared to the same quarter last year. During the same period in the previous year, the company earned $2.75 earnings per share. equities analysts predict that Gilead Sciences will post 8.53 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.73%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s payout ratio is 23.69%.
In related news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the transaction, the executive vice president now owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold 494,999 shares of company stock valued at $37,404,139 over the last 90 days. 1.30% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. Sage Capital Advisors llc bought a new stake in Gilead Sciences in the 3rd quarter valued at $275,000. Steward Partners Investment Advisory LLC bought a new stake in Gilead Sciences in the 3rd quarter valued at $1,309,000. Visionary Asset Management Inc. bought a new stake in Gilead Sciences in the 3rd quarter valued at $219,000. Public Employees Retirement System of Ohio increased its holdings in Gilead Sciences by 0.5% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 900,211 shares of the biopharmaceutical company’s stock valued at $72,935,000 after buying an additional 4,563 shares during the period. Finally, Orleans Capital Management Corp LA increased its holdings in Gilead Sciences by 63.2% in the 3rd quarter. Orleans Capital Management Corp LA now owns 17,017 shares of the biopharmaceutical company’s stock valued at $1,379,000 after buying an additional 6,588 shares during the period. 76.23% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Gilead Sciences, Inc. (GILD) Receives $84.40 Consensus Target Price from Analysts” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://ledgergazette.com/2017/12/13/gilead-sciences-inc-gild-receives-84-40-consensus-target-price-from-analysts.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.